To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

Innovative Protein Folding Predictions

A Revolutionary Breakthrough in Precision Medicine

Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine, EpiSelect™, utilizes computational discovery technologies to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.

About Our Science

A Growing Portfolio of Selective Antibody Therapeutic Product Candidates

Our portfolio leverages a revolutionary approach that enables the tailoring of therapeutic antibodies with a high degree of selectivity for the key drivers of multiple neurodegenerative and other misfolded protein diseases, including:

  • Alzheimer’s disease (AD)
  • Amyotrophic lateral sclerosis (ALS)
  • Frontotemporal dementia (FTD)
  • Multiple System Atrophy (MSA)
  • Parkinson’s disease (PD)
View Product Pipeline

Addressing Neurodegenerative and Other Misfolded Protein Diseases Using Novel Biologic Products

We are ProMIS Neurosciences, a leading clinical-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. Our large team of multidisciplinary experts is committed to the discovery and development of selective antibody therapies that combat neurodegenerative and other misfolded protein diseases at the source.

About Our Company

Latest News

View All News

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

View All News

Stock Snapshot